Xu Ran, Mao Yuqiang, Chen Kuanbing, He Wei, Shi Wenjun, Han Yun
Department of Thoracic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
Oncotarget. 2017 Jun 13;8(24):39177-39184. doi: 10.18632/oncotarget.16640.
Long non-coding RNAs (lncRNAs) are a family of non-protein-coding RNAs that might affect Lung adenocarcinoma (LAD) chemo-resistance and most of them could be used as biomarkers and therapy targets. However, the potential function of lncRNA ANRIL contributed paclitaxel chemo-resistance in LAD is still unknown. This study aimed to observe the expression of ANRIL in LAD, evaluate its biological role in the resistance of LAD cells to paclitaxel and explore the apoptosis role in the ANRIL associated mechanism. Our results showed that ANRIL functioning as a potential oncogene was up-regulated in LAD, and promoted the acquisition of chemo-resistance in paclitaxel partly through the mitochondrial pathway by modulating the expression of apoptosis-related protein cleaved-PARP and Bcl-2. These findings might improve LAD patients' paclitaxel treatment and made ANRIL to be a new target for paclitaxel-based chemotherapy in LAD.
长链非编码RNA（lncRNAs）是一类非蛋白质编码RNA，可能影响肺腺癌（LAD）的化疗耐药性，其中大多数可作为生物标志物和治疗靶点。然而，lncRNA ANRIL在LAD中导致紫杉醇化疗耐药的潜在功能仍不清楚。本研究旨在观察ANRIL在LAD中的表达，评估其在LAD细胞对紫杉醇耐药中的生物学作用，并探讨其在ANRIL相关机制中的凋亡作用。我们的结果表明，作为一种潜在癌基因的ANRIL在LAD中上调，并通过调节凋亡相关蛋白cleaved-PARP和Bcl-2的表达，部分通过线粒体途径促进了对紫杉醇化疗耐药性的获得。这些发现可能改善LAD患者的紫杉醇治疗，并使ANRIL成为LAD中基于紫杉醇化疗的新靶点。
